Chengdu Jiabao Yaoyin Pharmaceutical Technology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Chengdu Jiabao Yaoyin Pharmaceutical Technology - overview
Established
2019
Location
Chengdu, -, China
Primary Industry
Pharmaceuticals
About
Established in 2019 and based in Chengdu, China, Chengdu Jiabao Yaoyin Pharmaceutical Technology is a small-molecular innovation drug developer that focuses on infections, tumors and autoimmune diseases. The founder Dr. Yuquan Wei is the director of the Cancer Center of West China Hospital and has 30 years of experience in clinical research and cancer treatment. In August 2021, the company raised RMB 100 million in series Pre-A funding from new investors.
The company has self-developed product such as JDB0131 which is a drug used to treat drug-resistant tuberculosis, JDB153 which is a tumor immune and anti-tumor angiogenic drug, JDB175 is a BTK (Bruton's) inhibitor and JDB383 which is an inhibitor used to treat giant cell tumor of tendon sheath.
Current Investors
Ding Xiang Capital, Probe Capital
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.